Acute lymphoblastic leukemia other diagnostic studies: Difference between revisions
Carlos Lopez (talk | contribs) No edit summary |
Carlos Lopez (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Cytogenetics== | ==Cytogenetics== | ||
[[Cytogenetics]] (particularly the presence of [[Philadelphia chromosome]]) and [[immunophenotyping]], establish whether the "blast" cells began from the [[B lymphocyte]]s or [[T lymphocyte]]s. DNA testing can establish how aggressive the disease is; different mutations have been associated with shorter or longer survival. | *[[Cytogenetics]] (particularly the presence of [[Philadelphia chromosome]]) and [[immunophenotyping]], establish whether the "blast" cells began from the [[B lymphocyte]]s or [[T lymphocyte]]s. DNA testing can establish how aggressive the disease is; different mutations have been associated with shorter or longer survival. | ||
==Biopsy== | ==Biopsy== | ||
Revision as of 19:19, 24 August 2015
|
Acute lymphoblastic leukemia Microchapters |
|
Differentiating Acute lymphoblastic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute lymphoblastic leukemia other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Acute lymphoblastic leukemia other diagnostic studies |
|
FDA on Acute lymphoblastic leukemia other diagnostic studies |
|
CDC on Acute lymphoblastic leukemia other diagnostic studies |
|
Acute lymphoblastic leukemia other diagnostic studies in the news |
|
Blogs on Acute lymphoblastic leukemia other diagnostic studies |
|
Directions to Hospitals Treating Acute lymphoblastic leukemia |
|
Risk calculators and risk factors for Acute lymphoblastic leukemia other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Cytogenetics
- Cytogenetics (particularly the presence of Philadelphia chromosome) and immunophenotyping, establish whether the "blast" cells began from the B lymphocytes or T lymphocytes. DNA testing can establish how aggressive the disease is; different mutations have been associated with shorter or longer survival.
Biopsy
- A biopsy is the only sure way to know whether leukemia cells are in the bone marrow. Before the sample is taken, local anesthesia is used to numb the area. This helps reduce the pain. Bone marrow from your hipbone or another large bone is taken as biopsy.[1]
- A bone marrow biopsy and aspirate are routinely performed even in T-cell ALL to determine the extent of marrow involvement. Malignant cells should be sent for conventional cytogenetic studies, as detection of the Ph1 t(9;22), myc gene rearrangements (in Burkitt leukemia), and MLL gene rearrangements add important prognostic information[2]
Flow cytometry
- Flow cytometry should be performed to characterize expression of lineage-defining antigens and allow determination of the specific ALL subtype.[2]
RT-PCR and FISH
- In addition, for B-cell disease, the malignant cells should be analyzed using RT-PCR and FISH for evidence of the bcr-abl fusion gene. This last point is of utmost importance, as timely diagnosis of Ph1 ALL will significantly change the therapeutic approach.
References
- ↑ Harrison's Principles of Internal Medicine, 16th EditioN, Chapter 97. Malignancies of Lymphoid Cells. Clinical Features, Treatment, and Prognosis of Specific Lymphoid Malignancies.
- ↑ 2.0 2.1 "National Cancer Institute".